What happens to psychosis risk when cannabis becomes easier to access? According to this Canadian study, the risk goes up. Shuichi Suetani explores what we can learn from one of the countries leading the way in drug policy reform.
[read the full story...]
Shuichi Suetani and Sarah Thomas highlight new research from Korea which suggests that antipsychotic medications do seem to help reduce the relapse of schizophrenia in pregnant women.
[read the full story...]
Lorna Staines discusses a recent Swedish cross-sectional study of 16,255 adolescent twins, which looks at the mental health risks of using psychedelics in the real world.
[read the full story...]
Kalya Win Aung, Angela Kibia and Dorothy Williams consider a systematic review and network meta-analysis published by the Lancet Psychiatry on psychological and psychosocial interventions for treatment-resistant schizophrenia.
[read the full story...]
Laura Naysmith summarises a study of menopausal hormone therapy (also known as HRT), which suggests the treatment is linked with reduce the risk of psychosis relapse in menopausal women.
[read the full story...]
David Mongan reports on a recent trial of omega-3 supplementation for the prevention of psychosis in people at ultra-high risk, which finds no evidence of a positive effect. He reflects on these findings and considers what’s next for the field.
[read the full story...]
Nuala Murray explores a recent Australian case-control study that looks at the associations between changes in gut microbiota and schizophrenia diagnosis, treatment resistance, and clozapine response.
[read the full story...]
Yuri Milaneschi discusses new research on the structure and presentation of mental health disorders, which suggests that although there are many different faces of major mental disorders, some of these faces are far more common than others.
[read the full story...]
Dhea Bengardi summarises a systematic review exploring the prevalence of different types of neglect across a wide variety of mental health conditions.
[read the full story...]
Nicola Rizzo Pesci and Andrea Cipriani summarise findings from the EMERGENT-2 trial spotlighting a promising new drug treatment for schizophrenia.
[read the full story...]
